Edotecarin

Summary

Edotecarin (CHEMBL435191) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including glioblastoma and gastric neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 608.6 Da · C29H28N4O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL435191
Name	Edotecarin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9808998
Molecular formula	C29H28N4O11
Molecular weight	608.6
InChIKey	QMVPQBFHUJZJCS-NTKFZFFISA-N

SMILES: C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O

IUPAC name: 13-(1,3-dihydroxypropan-2-ylamino)-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione

Also known as: Edotecarin, Edotecarina, Edotecarine, J-107088, PF-804950, NB-506 Analogue, edotecarin, EDOTECARIN

Patent coverage: 458 distinct patent families (1,181 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,098 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: DNA topoisomerase 1, DNA topoisomerase 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q04750	8.82	EC50	1.5	nM	CHEMBL_ACT_2511675
TOP1	7.29	EC50	51	nM	CHEMBL_ACT_19439596
TOP1	7.29	EC50	51	nM	CHEMBL_ACT_447732
TOP1	7	EC50	100	nM	CHEMBL_ACT_2511770

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioblastoma	3	MONDO:0018177	EFO:0000519
gastric neoplasm	2	MONDO:0021085	EFO:0003897
breast neoplasm	2	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00068952	PHASE3	COMPLETED	Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
NCT00067314	PHASE2	COMPLETED	Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
NCT00070031	PHASE2	COMPLETED	Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy
NCT00087503	PHASE2	COMPLETED	Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
NCT00072332	PHASE1	COMPLETED	Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).